Sat, Aug 30, 2014, 4:39 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

OncoMed Pharmaceuticals, Inc. Message Board

tanweikate 3 posts  |  Last Activity: Jun 26, 2014 3:18 AM Member since: Apr 8, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Drug efficacy and side effects datas

    by tanweikate Jun 22, 2014 8:21 AM
    tanweikate tanweikate Jun 26, 2014 3:18 AM Flag

    Absolutely agreed. As Paul Hastings said there were "multiple shoots on the goal". Also the statement that OMED is going to retain full benefits for the new pathways shows managements confidence. One article published in 2011 expresses one persons opinion, and it would be a joke that celgene wasn't aware of the negative opinion but the fact that the deal was signed shows that its promising as evidenced by the excellent clinical outcomes.

  • Please read drug fact sheets of the standard cancer therapy Gemcitabine and the newly approved combination of ABRAXANE & gemcitabine:
    Median Overall Survival (months)
    ABRAXANE & gemcitabine


    Median Overall Survival (months)
    8.5 6.7
    Median Progression-free Survival (months)
    5.5 3.7
    Overall Response Rate

    Confirmed complete or partial overall response
    23% 7%

    OMED's leading drug Demcizumab in combination with ABRAXANE & gemcitabine achieved 90% partial response rate. This has to be GREAT for patients and INVESTORS!

  • tanweikate tanweikate Jun 4, 2014 9:22 PM Flag

    Please read OMED's last proxy statement. It explained in length of the NEO's compensation in event of change in control, and in the end, in the "other matters" it says that it's the board's decision not to disclose something at the moment, and that such matter will be voted by shareholders on board's recommendation.

    Sentiment: Strong Buy

20.29-1.29(-5.98%)Aug 29 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.